*Time

Topic

October 25, 2025

7:00–7:55 AM

Registration and Breakfast

7:55–8:00 am

Welcome and Introductions

Suresh Ramalingam, MD, FACP, FASCO
Ticiana A. Leal, MD

Plenary 1: Early-Stage NSCLC/Locally Advanced NSCLC: Multidisciplinary Integration of Neoadjuvant, Surgical, and Adjuvant Therapies

Co-Chairs: Ticiana Leal, MD and Ioana Bonta, MD

8:00–8:15 am

Optimal Approach to Perioperative Management of Resectable NSCLC Without Driver Mutations

Heather Wakelee, MD

8:15–8:30 am

Targeted Therapy for Oncogene-Addicted Early-Stage NSCLC

Jamie E. Chaft, MD

8:30–8:45 am

Using MRD Status to Guide Therapy for Early-Stage NSCLC

Marina Chiara Garassino, MD

8:45–9:00 am

Surgical Considerations in the Era of Perioperative Therapies

Onkar Khullar, MD, MSc

9:00–9:15 am

Innovations in Unresectable Stage III NSCLC Without Driver Mutations

Paul Bunn, MD

9:15–9:30 am

Panel Discussion

9:30–10:15 am

Morning Symposium and Exhibits

Plenary 2: Advanced NSCLC/SCLC

Co-Chairs: Kristin Higgins, MD and Mohan Krishnamachary, MD

10:15–10:30 am

New Standards in SCLC

Ticiana Leal, MD

10:30–10:45 am

Will ADCs Be Incorporated in 1L NSCLC Without Driver Mutations?

Joshua K. Sabari, MD

10:45–11:10 am

Radiation Therapy Is Effective for Management of Oligometastatic NSCLC

Yes: Sibo Tian, MD (10 min)
No: Stephen Liu, MD (10 min)
Rebuttals (5 min)

11:10–11:25 am

Panel Discussion

11:25 am–12:10 pm

Lunch Symposium and Exhibits

Plenary 3: Targeted Therapy in Advanced NSCLC

Co-Chairs: Jennifer W. Carlisle, MD and Harpaul (Paul) Gill, MD

12:10–12:25 pm

EGFR-Targeted Therapy in Locally Advanced and Advanced NSCLC

Suresh Ramalingam, MD, FACP, FASCO

12:25–12:40 pm

Is There Room for Novel Next-Generation ALK TKIs in 1L ALK+ NSCLC?

Shirish M. Gadgeel, MD

12:40–1:05 pm

DEBATE: Should KRAS G12C Inhibitors Be Given With Immunotherapy for Maximal Efficacy?

Yes: Jennifer Carlisle, MD (10 min)
No: Gregory J. Riely, MD (10 min)
Rebuttals (5 min)

1:05–1:20 pm

Panel Discussion

1:20–1:35 pm

Afternoon Break and Exhibits

Plenary 4: Targeted Therapy in Advanced NSCLC II and Rare Thoracic Malignancies

Co-Chairs: Laercio L. DaSilva, MD and Steve L. McCune, MD, PhD

1:35–1:50 pm

EGFR Exon 20 Insertions and HER2 Mutations

John Heymach, MD

1:50–2:05 pm

RET, ROS1, and NTRK Fusions: Optimal Therapy and Emerging Agents

Conor E. Steuer, MD

2:05–2:20 pm

Targeting MET and BRAF

Gregory J. Riely, MD

2:20–2:35 pm

Tackling Leptomeningeal Disease in NSCLC With Driver Mutations

Kelsey Pan, MD, MPH

2:35–2:50 pm

Rare Thoracic Malignancies: What’s New in Mesothelioma and Thymic Malignancies

Fatemeh Ardeshir, MD, MSc

2:50–3:05 pm

Panel Discussion

3:05–3:20 pm

Closing Remarks and Adjourn

*Times provided in ET.

Agenda subject to change.